Outcomes of the Endoscopic Endonasal Approach for the Treatment of Clival Chordomas: A Single-Center Experience

Abstract

Objective Chordoma is a low-grade malignant tumor that originates from the remnant tissue of the embryonic notochord. Postoperative or definitive radiotherapy (RT) has been used to enhance local control. This study aims to assess the outcomes of the expanded endoscopic endonasal approach (EEA) for maximal removal of clival chordomas followed by RT for visualized residual or tumor recurrence.

Materials and Methods A retrospective review was performed on consecutive patients with clival chordoma who underwent endoscopic endonasal resection in the otorhinolaryngology and neurosurgery departments, between 2016 and 2021. We included all patients with pathologically confirmed clival chordoma who were treated using the EEA. Patients who underwent combined external and endoscopic approaches or transcranial surgery were excluded.

Results Seventeen patients were included in this study. Most of them had tumors located in the middle clivus. Regarding RT, the majority of patients underwent postoperative RT. Almost half of them underwent CyberKnife (CK) RT. None of them had severe toxicities (grade 3 or higher). Three patients died, resulting in a mortality rate of 17.6% none of them related to radiation side effect. The 2-year overall survival was 82.4% (mean standard error [SE] = 1.765, 95% confidence interval [CI] = 1.505–2.024), and the progression-free survival (PFS) was 76.5% (mean SE = 3.403, 95% CI = 2.791–4.016). No distal metastasis was reported in our series.

Conclusion This series demonstrates that expanded endoscopic endonasal approach (EEA) for the resection of skull base chordomas, followed by CyberKnife radiosurgery, presents a viable alternative to proton beam therapy; however, further research is necessary to directly compare these modalities.

Keywords

chordoma - endoscopic endonasal approach - clivus - skull base - radiotherapy

Publikationsverlauf

Eingereicht: 19. Juli 2023

Angenommen: 18. Oktober 2023

Accepted Manuscript online:
26. Oktober 2023

Artikel online veröffentlicht:
04. Dezember 2023

• References

• 1 Teng C, Yang Q, Xiong Z, Ye N, Li X. Multivariate analysis and validation of the prognostic factors for skull base chordoma. Front Surg 2021; 8: 764329
• 2 Takagi M, Demizu Y, Nagano F. et al. Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study. Radiat Oncol 2018; 13 (01) 232
• 3 Shen Y, Li M, Xiong Y. et al. Proteomics analysis identified ASNS as a novel biomarker for predicting recurrence of skull base chordoma. Front Oncol 2021; 11: 698497
• 4 Wang L, Wu Z, Tian K. et al. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients. J Neurosurg 2017; 127 (06) 1257-1267
• 5 Alahmari M, Temel Y. Skull base chordoma treated with proton therapy: a systematic review. Surg Neurol Int 2019; 10: 96
• 6 Snyderman CH, Gardner PA. Current opinion in otolaryngology and head and neck surgery: clival chordoma and its management. Curr Opin Otolaryngol Head Neck Surg 2020; 28 (02) 118-121
• 7 al-Mefty O, Borba LAB. Skull base chordomas: a management challenge. J Neurosurg 1997; 86 (02) 182-189
• 8 Roy A, Warade A, Jha AK, Misra BK. Skull base chordoma: long-term observation and evaluation of prognostic factors after surgical resection. Neurol India 2021; 69 (06) 1608-1612
• 9 Chen G, Li M, Xu W. et al. Surgical outcomes of clival chordoma through endoscopic endonasal approach: a single-center experience. Front Endocrinol (Lausanne) 2022; 13: 800923
• 10 Wang K, Gao D, Pan J, Bao E, Sun S. The role of Gamma Knife radiosurgery in the management of skull base chordoma. Front Oncol 2023; 12: 1046238
• 11 Ogawa Y, Jokura H, Tominaga T. Midterm prognosis and surgical implication for clival chordomas after extended transsphenoidal tumor removal and Gamma Knife radiosurgery. BMC Neurol 2021; 21 (01) 207
• 12 Liu AL, Wang ZC, Sun SB, Wang MH, Luo B, Liu P. Gamma Knife radiosurgery for residual skull base chordomas. Neurol Res 2008; 30 (06) 7-8
• 13 Hug EB, Pelak M, Frank SJ, Fossati P. A review of particle therapy for skull base tumors: modern considerations and future directions. Int J Part Ther 2021; 8 (01) 168-178
• 14 Hug EB, Loredo LN, Slater JD. et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999; 91 (03) 432-439
• 15 Weber DC, Malyapa R, Albertini F. et al. Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol 2016; 120 (01) 169-174
• 16 Noël G, Feuvret L, Calugaru V. et al Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncologica 2005; 44 (07) 700-708